Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-624-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.50 million
Profitability
Miscellaneous
Employees130
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company earned $7.14 million during the quarter, compared to the consensus estimate of $6.81 million. Cytokinetics had a negative net margin of 308.73% and a negative return on equity of 575.21%. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
6 analysts have issued twelve-month target prices for Cytokinetics' shares. Their predictions range from $16.00 to $26.00. On average, they expect Cytokinetics' share price to reach $20.17 in the next year. This suggests a possible upside of 74.5% from the stock's current price. View Analyst Price Targets for Cytokinetics.
What is the consensus analysts' recommendation for Cytokinetics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.
Has Cytokinetics been receiving favorable news coverage?
News stories about CYTK stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytokinetics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Cytokinetics.
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Genmab A/S (GMAB), Myokardia (MYOK), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Ra Pharmaceuticals (RARX), PTC Therapeutics (PTCT), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Cambrex (CBM), Ligand Pharmaceuticals (LGND), Intercept Pharmaceuticals (ICPT), Xencor (XNCR) and Zai Lab (ZLAB).
What other stocks do shareholders of Cytokinetics own?
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.10%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Cytokinetics stock include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Institutional Ownership Trends for Cytokinetics.
Which major investors are buying Cytokinetics stock?
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $11.56.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $678.34 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.
What is Cytokinetics' official website?
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
